article thumbnail

Biologics and Biosimilars Landscape: IP, Policy, and Market Developments

JD Supra Law

In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price Competition and Innovation Act (BPCIA), post-grant disputes on biologic drug patents before the United States Patent and Trademark Office (USPTO), and proposed legislation (..)

article thumbnail

5 Litigation Funding Trends To Note In 2024

IP Law 360

Over the next year and beyond, litigation funding will continue to evolve in ways that affect attorneys and the larger litigation landscape, from the growth of a secondary market for funded claims, to rising interest rates restricting the availability of capital, says Jeffery Lula at GLS Capital.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Event reminder - Pharma and Biotech Patent Litigation Summit

The IPKat

New acquisition: Merpel and Girl with a Pearl Earring As The IPKat reported a while ago, on 22-24 January 2024, the Pharma and Biotech Patent Litigation Summit will return to Amsterdam (Netherlands). A UPC Litigation Forum will take place on 22 January too. Speakers include judges from the UK, EPO, USA and the UPC.

article thumbnail

AIPPI Congress (Report 2): Ethics in Funding IP Litigation

The IPKat

One panel session she was unable to get to was on the Ethics in Funding IP Litigation moderated by Gustavo de Freitas Morais ( Managing Partner at Dannemann Siemsen ). Over to Emily : "The panel started by introducing the different structures for financing litigation. The panel examined the funding business model.

article thumbnail

Litigation as a Source of Profit? Non-Practicing Entities and Patent Litigation

IPilogue

Litigation is almost always recommended to be avoided , whether because of the sheer amount of time needed to get a court date, the expensive costs for the client and law firm, or the risks associated with receiving an unfavorable judgement. Michelle Mao is an incoming 2L JD student at Osgoode Hall Law school and an IPilogue Writer.

article thumbnail

The IP-backed finance and litigation funding markets revolution

IAM Magazine

Insurance policy types are proliferating and the increased certainty is attracting new lenders – a virtuous circle that looks set to cut capital costs for IP-rich companies

article thumbnail

The IP-backed finance and litigation funding markets revolution

IAM Magazine

Insurance policy types are proliferating and the increased certainty is attracting new lenders – a virtuous circle that looks set to cut capital costs for IP-rich companies